[go: up one dir, main page]

CL2012000327A1 - Composicion farmaceutica resistente a corrosion y estable para inhalador presurizado de dosis medida que contiene un ingrediente activo suspendido y otro disuelto, un haluro disuelto, un cosolvente, un propulsor, entre 0,1 y 10 % de agua, 0,0001 y 0,01 % de un acido organico y 0,01 a 0,3 % de agente suspensor insaturado; metodo de preparacion. - Google Patents

Composicion farmaceutica resistente a corrosion y estable para inhalador presurizado de dosis medida que contiene un ingrediente activo suspendido y otro disuelto, un haluro disuelto, un cosolvente, un propulsor, entre 0,1 y 10 % de agua, 0,0001 y 0,01 % de un acido organico y 0,01 a 0,3 % de agente suspensor insaturado; metodo de preparacion.

Info

Publication number
CL2012000327A1
CL2012000327A1 CL2012000327A CL2012000327A CL2012000327A1 CL 2012000327 A1 CL2012000327 A1 CL 2012000327A1 CL 2012000327 A CL2012000327 A CL 2012000327A CL 2012000327 A CL2012000327 A CL 2012000327A CL 2012000327 A1 CL2012000327 A1 CL 2012000327A1
Authority
CL
Chile
Prior art keywords
dissolved
cosolvent
propellant
unsaturated
suspended
Prior art date
Application number
CL2012000327A
Other languages
English (en)
Inventor
Julio Cesar Vega
Original Assignee
Laboratorio Pablo Cassara Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45607025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorio Pablo Cassara Srl filed Critical Laboratorio Pablo Cassara Srl
Publication of CL2012000327A1 publication Critical patent/CL2012000327A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2012000327A 2011-02-10 2012-02-08 Composicion farmaceutica resistente a corrosion y estable para inhalador presurizado de dosis medida que contiene un ingrediente activo suspendido y otro disuelto, un haluro disuelto, un cosolvente, un propulsor, entre 0,1 y 10 % de agua, 0,0001 y 0,01 % de un acido organico y 0,01 a 0,3 % de agente suspensor insaturado; metodo de preparacion. CL2012000327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/024,414 US20120204871A1 (en) 2011-02-10 2011-02-10 Stable, non-corrosive formulations for pressurized metered dose inhalers

Publications (1)

Publication Number Publication Date
CL2012000327A1 true CL2012000327A1 (es) 2014-07-11

Family

ID=45607025

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000327A CL2012000327A1 (es) 2011-02-10 2012-02-08 Composicion farmaceutica resistente a corrosion y estable para inhalador presurizado de dosis medida que contiene un ingrediente activo suspendido y otro disuelto, un haluro disuelto, un cosolvente, un propulsor, entre 0,1 y 10 % de agua, 0,0001 y 0,01 % de un acido organico y 0,01 a 0,3 % de agente suspensor insaturado; metodo de preparacion.

Country Status (7)

Country Link
US (2) US20120204871A1 (es)
EP (1) EP2486914A3 (es)
AR (1) AR085059A1 (es)
BR (1) BR102012002923A2 (es)
CL (1) CL2012000327A1 (es)
DE (1) DE102012102218A1 (es)
MX (2) MX353975B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
WO2016164508A1 (en) * 2015-04-10 2016-10-13 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
WO2016187156A1 (en) * 2015-05-21 2016-11-24 Island Breeze Systems Ca, Llc Propellant based metered dose inhaler and food applicators and applicators
EA202092976A1 (ru) * 2018-06-04 2021-03-16 Люпин Инк. Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением
IL305534A (en) * 2021-03-23 2023-10-01 1232176 B C Ltd device for the treatment of anaphylaxis
WO2025128797A1 (en) 2023-12-13 2025-06-19 Blue Evolution, Inc Ecofriendly, biodegradable biological polysaccharide composition for packaging materials

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4132176C2 (de) 1991-09-27 1997-03-13 Ig Spruehtechnik Gmbh Dosieraerosole mit Isobutan als Treibmittel
ATE171865T1 (de) 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
RO117414B1 (ro) 1992-12-09 2002-03-29 Jager Paul D Waterbury Compozitie farmaceutica de aerosol in solutie
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6739333B1 (en) 1999-05-26 2004-05-25 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
ME00420B (me) * 2003-03-20 2011-12-20 Boehringer Ingelheim Pharmaceuticals Inc Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
UA99466C2 (en) * 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound

Also Published As

Publication number Publication date
US20120204871A1 (en) 2012-08-16
AR085059A1 (es) 2013-08-07
MX2012003303A (es) 2012-09-18
DE102012102218A1 (de) 2013-06-20
MX353975B (es) 2018-02-07
US20120207685A1 (en) 2012-08-16
EP2486914A2 (en) 2012-08-15
BR102012002923A2 (pt) 2013-07-23
EP2486914A3 (en) 2012-09-05
MX2012001693A (es) 2012-08-29

Similar Documents

Publication Publication Date Title
CL2012000327A1 (es) Composicion farmaceutica resistente a corrosion y estable para inhalador presurizado de dosis medida que contiene un ingrediente activo suspendido y otro disuelto, un haluro disuelto, un cosolvente, un propulsor, entre 0,1 y 10 % de agua, 0,0001 y 0,01 % de un acido organico y 0,01 a 0,3 % de agente suspensor insaturado; metodo de preparacion.
AR130238A2 (es) Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de un envase de aerosol asociado
MX2021000482A (es) Composiciones de fenfluramina y métodos de preparación de las mismas.
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
CL2011002053A1 (es) Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel.
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
EP2792746A4 (en) OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
BR112013029202A2 (pt) solução farmacêutica, recipiente selado, inalador de dose medida, método para tratar um paciente que sofre ou que está susceptível a sofrer de um distúrbio respiratório, usos de um propelente, de uma composição farmacêutica, e, de um aparelho de administração de medicamentos que contém uma composição farmacêutica
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
UY30139A1 (es) Formulacion farmaceuica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
AR092960A1 (es) Procedimiento para preparar compuestos tienopirimidina
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
MX2022009231A (es) Inhalador de polvo seco y metodo de uso.
AR089302A1 (es) Un medicamento inhalable
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
BR112013006632A2 (pt) composições e sistema de liberação de distribuição de droga aprimorados
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
Tushar et al. Local infiltration analgesia following total hip replacement: a review of current literature
BRPI0607990A2 (pt) formulação de um aerossol farmacêutico para inaladores dosimetrados pressurizados contendo um agente seqüestrante, uso do agente sequestrante, inalador de dosimetrado pressurizado e método de preenchimento do inalador de aerossol
CO7310521A2 (es) Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
FR2937867B1 (fr) Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.